25 results on '"Giessen, Clemens"'
Search Results
2. Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer
3. Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer
4. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma—Very good response predominantly in patients with intestinal type tumors
5. Combined resection of colorectal hepatic–pulmonary metastases shows improved outcome over chemotherapy alone
6. Early tumor shrinkage in metastatic colorectal cancer: Retrospective analysis from an irinotecan-based randomized first-line trial
7. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
8. Predictors of EGF receptor monoclonal antibody activity in metastatic colorectal cancer: current status
9. Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant
10. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
11. Neo FLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
12. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
13. Surrogate endpoints in second-line treatment for mCRC: A systematic literature-based analysis from 23 randomised trials.
14. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut).
15. Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.
16. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial.
17. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer.
18. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.
19. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
20. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.
21. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer
22. O-0009QUANTITATIVE ANALYSIS OF THE IMPACT OF DEEPNESS OF RESPONSE ON POST-PROGRESSION SURVIVAL TIME FOLLOWING FIRST-LINE TREATMENT IN PATIENTS WITH MCRC.
23. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
24. Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.
25. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.